Pharma and biotech pipelines are full of precision and targeted medicines. In Europe, traditional payment and rebate processes are not built for this new generation of therapies that often require complex, multi-party, indication-based, and combination pricing negotiations.

 

Many of these next-generation therapies have been approved by regulators, but are not yet reimbursed because of pricing negotiation delays or challenges.  This means patients are not getting the medicines they need, pharma companies are not selling their newest therapies, and payers and providers are not able to serve some patients. 

 

A new model is needed…

 PharmaCCX is a pricing platform for a new generation of indication and combination oncology therapies in Europe.

 

PharmaCCX is an independent, third-party technology platform focused on the oncology drug market in Europe where parties can dynamically negotiate prices based on scientific evidence and economic analysis, expediting the negotiation process and patient access to medicines.

 
Test

1. Negotiation Triggered

A new therapy receives approval, existing pricing contract expires, or some other event triggers the need to negotiate a new pricing and rebate contract.

Screen+Shot+2019-08-02+at+12.06.50+PM.jpg

2. Pricing Negotiation

Pharma and payers use PharmaCCX tech platform to seamlessly manage and negotiate pricing. Platform facilitates exchange of “contingent commitments,” expressions of willingness to accept particular pricing under conditions that must be met.

Screen+Shot+2019-08-02+at+12.06.57+PM.jpg

3. Term Sheet Produced

Deal term sheet is generated if and when a contingent commitment produces a match (i.e. all conditions are met) across all parties.

Screen+Shot+2019-08-02+at+12.07.04+PM.jpg

4. Access to Medicines

Patients receive access to needed therapies, payers can better serve patient needs, and pharma deploys novel therapies to a new or an additional market.

Leadership Team

Our team has extensive experience and deep industry knowledge across pharmaceutical, healthcare, financial services, and technology industries.

NATHAN SIGWORTH     CO-FOUNDER & CEO   Nathan was previously co-founder and CEO of PharmaSecure where he helped accelerate adoption of serialization as the standard in global pharmaceutical supply chain. Nathan is a graduate of Dartmouth College.

NATHAN SIGWORTH

CO-FOUNDER & CEO

Nathan was previously co-founder and CEO of PharmaSecure where he helped accelerate adoption of serialization as the standard in global pharmaceutical supply chain. Nathan is a graduate of Dartmouth College.

RICHARD BERGSTROM     CO-FOUNDER & CUSTOMER DEVELOPMENT   Richard was previously Director General of EFPIA and worked in regulatory affairs at Roche and Novartis. He has also served as Director of EU Regulatory Strategy at Roche and Director-General of LIF.

RICHARD BERGSTROM

CO-FOUNDER & CUSTOMER DEVELOPMENT

Richard was previously Director General of EFPIA and worked in regulatory affairs at Roche and Novartis. He has also served as Director of EU Regulatory Strategy at Roche and Director-General of LIF.

PETER RICE     CHIEF OPERATING OFFICER   Prior to PharmaCCX Peter was Chief of Staff at Formlabs and held several roles at Alarm.com (ALRM) including Director of Program Management and rotations in Strategic Planning, Product Management, Supply Chain, and Finance. Peter is a graduate of Colby College (BA) and Thayer School of Engineering at Dartmouth College (BE, MEM).

PETER RICE

CHIEF OPERATING OFFICER

Prior to PharmaCCX Peter was Chief of Staff at Formlabs and held several roles at Alarm.com (ALRM) including Director of Program Management and rotations in Strategic Planning, Product Management, Supply Chain, and Finance. Peter is a graduate of Colby College (BA) and Thayer School of Engineering at Dartmouth College (BE, MEM).

ARMEN SOLAKHYAN     CHIEF TECHNOLOGY OFFICER   Before joining PharmaCCX, Armen served in design and development roles at Farallon Capital Management, LifeYield and Charles River where he led the development of Fixed Income Execution Platform as part of the Charles River IMS. He holds an M.S. in Computer Science from Armenian State Polytechnic Institute.

ARMEN SOLAKHYAN

CHIEF TECHNOLOGY OFFICER

Before joining PharmaCCX, Armen served in design and development roles at Farallon Capital Management, LifeYield and Charles River where he led the development of Fixed Income Execution Platform as part of the Charles River IMS. He holds an M.S. in Computer Science from Armenian State Polytechnic Institute.

 
JULIA F. BERNSTEIN    DIRECTOR   Julia serves on the Board of Directors of PharmaCCX. She is currently COO at Tempest. She has been a commercial leader at Ginger.io, Beacon Health Options, Institute on Aging, and McKinsey. Julia is a graduate of Stanford GSB and Dartmouth College.

JULIA F. BERNSTEIN

DIRECTOR

Julia serves on the Board of Directors of PharmaCCX. She is currently COO at Tempest. She has been a commercial leader at Ginger.io, Beacon Health Options, Institute on Aging, and McKinsey. Julia is a graduate of Stanford GSB and Dartmouth College.

 
BARATH SHANKAR SUBRAMANIAN    DIRECTOR   Barath joined Accel in 2012 and serves on the PharmaCCX Board of Directors. He has been in the healthcare domain for over a decade, having previously been a senior consultant at Frost & Sullivan covering healthcare and life sciences. Barath has a bachelor’s degree in Pharmacy from BITS, Pilani and an MBA from Carnegie Mellon University.

BARATH SHANKAR SUBRAMANIAN

DIRECTOR

Barath joined Accel in 2012 and serves on the PharmaCCX Board of Directors. He has been in the healthcare domain for over a decade, having previously been a senior consultant at Frost & Sullivan covering healthcare and life sciences. Barath has a bachelor’s degree in Pharmacy from BITS, Pilani and an MBA from Carnegie Mellon University.

 
 

Our Investors

 
 

Company Principles

 

 #1 Independent

We are independent, non-partisan, and do not take sides. We work collaboratively with our stakeholders to govern the platform.

2# don’t sell data

We are not in the data business. We do not own and sell data; we only process data on behalf of our users.

#3 market Competition

We believe more effective market competition is needed on top of health economic assessments.

 
 

#4 Value-Based Pricing

We believe in value-based pricing, but also understand the budgetary constraints of payers and consumers.

 

#5 collaboration

We aim to catalyze a new ecosystem for pricing negotiations through partnership with the current ecosystem of pricing advisors, real-world data providers, and others with experience and expertise.

 
 
 

Global Offices

 
 

Boston

200 Portland Street
Boston, MA 02114

 
 
 

Stockholm

Malmskillandsgatan 32
6th Floor
111 51 Stockholm

 
 
 

San Francisco

400 Concar Drive
San Mateo, CA 94402

 
 
 

Zug

Baarerstrasse 2
CH-6302 Zug, Switzerland